p16 INK4A/p19 ARF/p14 ARF (CDKN2A) Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of p16 INK4A/p19 ARF/p14 ARF (CDKN2A) monoclonal antibodies for research in cell cycle regulation and tumor suppression. p16 INK4A/p19 ARF/p14 ARF (CDKN2A) Antibodies are available for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). p16 INK4A/p19 ARF/p14 ARF (CDKN2A) functions as a key regulator in cell cycle control and prevents uncontrolled cell proliferation, making it essential in cancer research. Dysregulation of CDKN2A is frequently observed in various malignancies, highlighting its significance as a tumor suppressor. Research focused on p16 INK4A/p19 ARF/p14 ARF (CDKN2A) continues to reveal new insights into cancer development and potential therapeutic approaches. Scientists can effectively investigate cell cycle checkpoints and their role in cancer progression using p16 INK4A/p19 ARF/p14 ARF (CDKN2A) monoclonal antibodies. Understanding p16 INK4A/p19 ARF/p14 ARF (CDKN2A) mechanisms has led to significant discoveries in tumor biology and cancer treatment strategies. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of cancer pathways and contribute to the development of new therapeutic strategies.